Scientific Program

The primary focus of EVF’s scientific program is on facilitating translational research from discovery to early phase I/II clinical development.

Collaborations with different academic groups

Since its inception, EVF has successfully collaborated with different academic groups and supported the development of a number of HIV vaccine candidates from bench to clinic.

EVF has sponsored or co-sponsored multiple phase I/II HIV Vaccine Trials in Europe and Africa, in both prophylactic and therapeutic settings. These trials are funded and co-funded by European Commission 5th and 7th Framework Programs, Agence nationale de recherches sur le sida et les hépatites virales (ANRS) of Inserm, International HIV Vaccine Trial Network (IAVI), HIV Vaccine Trial Network(HVTN)/National Institute of Health (NIH) and European and Developing Countries Clinical Trials Partnership (EDCTP).

More recently, EVF is expanding its portfolio to other infectious disease areas through providing scientific project management support to large research consortia with the focus on facilitating the development from bench to clinic. To this end, EVF engages a pool of experts from manufacturing, to regulatory to clinical trials.

Bench to Clinic

EVF has successfully supported the development of a number of HIV vaccine candidates from bench to clinic. These include: 

The development of DNA, NYVAC and DREP, has been funded by European Commission framework programs and the Collaboration for AIDS Vaccine Discovery (CAVD) of the Bill and Melinda Gates Foundation (BMGF).

In addition, EVF has also provided support to other research groups in product development activities, such as the HIV SOSIP trimer vaccines in EHVA, and the COBRA flu vaccine in INCENTIVE.

HIV Vaccine Trials

EVF has sponsored or co-sponsored multiple phase I/II clinical trials in Europe and Africa, in both prophylactic and therapeutic settings.

These trials are funded and co-funded by European Commission 5th and 7th Framework and Horizon 2020 Programs, Agence nationale de recherches sur le sida et les hépatites virales (ANRS) of Inserm, International HIV Vaccine Trial Network (IAVI), HIV Vaccine Trial Network (HVTN)/National Institute of Health (NIH) and European and Developing Countries Clinical Trials Partnership (EDCTP).

Non-HIV Research Projects

Building on the experience it has gained in the HIV vaccine field, EVF has established collaborations in other infectious disease areas through providing scientific project management support focusing on facilitating the development from bench to clinic.

Protocol. Nr. Description Sponsor(s) Trials Sites Status Results
EHVA-P01 A phase I, prophylactic HIV vaccine trial to evaluate the safety and immunogenicity of HIV Clade C DREP alone and in Combination with a Clade C ENV protein in healthy HIV-uninfected adults. Inserm France, Switzerland, UK Ongoing NCT04844775
ANRS VRI06 A phase I multicenter double-blind placebo controlled dose escalation trial of an adjuvanted anti-cd40 mab fused to env gp140 hiv clade c zm-96 (cd40.hivri.env) vaccine combined or not with a dna-hiv-pt123 hiv-1 vaccine in healthy participants Inserm France, Switzerland Completed NCT04842682 2023 CROI
PV1 (PrEPVac) A Phase IIb three-arm, two-stage HIV prophylactic vaccine trial with a second randomisation to compare TAF/FTC to TDF/FTC as pre-exposure prophylaxis (PrEPVacc) Imperial College London Uganda, Tanzania, South Africa, Mozambique Ongoing NCT04066881
HVTN111 A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIVuninfected adult participants DAIDS, NIH South Africa, Tanzania, Zambia Completed NCT02997969 Hosseinipour 2020
HVTN108 A phase 1/2a clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA, and of MF59®- or AS01B-adjuvanted clade C Env protein in various combinations, in healthy, HIV-uninfected adult participants DAIDS, NIH US, South Africa Completed NCT02915016 Manuscript under submission
HVTN105 A phase 1b clinical trial to evaluate the safety and immunogenicity of different combinations of DNA-HIV-PT123 and AIDSVAX® B/E in healthy, HIV uninfected adult participants DAIDS, NIH US Completed NCT02207920 Rouphael 2019
EV07 An open label phase I clinical trial to evaluate the effect of late boost on HIV-uninfected vaccinees from EV06 trial EVF Uganda Completed NCT03391375 Manuscript in  preparation
EV06 A phase I double blind placebo-controlled clinical trial to evaluate the safety and immunogenicity of the combination of DNA-HIV-PT123 and AIDSVAX®B/E in HIV-1-uninfected adult participants with or without underlying Schistosoma mansoni infection EVF Uganda Completed NCT02516306 Manuscript in preparation
HVTN096/ EV04 A phase I double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus NYVAC + AIDSVAX® B/E, and DNA alone versus DNA + AIDSVAX® B/E when followed by NYVAC + AIDSVAX® B/E boosts in healthy, HIV-1-uninfected adult participants DAIDS/ EVF Switzerland Completed NCT01799954 Pantaleo 2019
HVTN092 A phase I clinical trial to evaluate safety and to compare the immunogenicity of 3 DNA vaccine Prime schedules followed by a NYVAC vaccine boost in healthy, HIV-1 uninfected adult participants DAIDS Switzerland, US Discontinued NCT01783977
HVTN078 A phase Ib clinical trial to evaluate the safety and immunogenicity of heterologous prime/boost vaccine regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC-B) in healthy, HIV-1 uninfected, Ad5 seronegative adult participants DAIDS / EVF Switzerland Completed NCT00961883 Bart 2014
EV03/ ANRSVAC20 Phase II Immunogenicity and safety of 3 DNA-C prime followed by 1 NYVAC-C boost versus 2 DNA-C prime followed by 2 NYVAC-C boost EVF/ ANRS Switzerland, UK, Germany, France Completed NCT00490074 Levy 2020
EV02 Phase I Safety and Immunogenicity comparing DNA-C prime and NYVAC-C boost versus NYVAC-C alone EVF Switzerland, UK Completed Harari 2008McGormack 2008EV02 press release
EV01 Phase I Safety and Immunogenicity Study of NYVAC-C alone Imperial College London Switzerland, UK Completed EV01 Result Press releaseBart 2008
Protocol. Nr.DescriptionSponsor(s)Trials SitesStatusResults
TheraVac01Phase I
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected ART-treated HIV patients
EVFSwitzerlandCompletedHarari 2012
TheraVac02Phase I
safety of MVA-B in chronic HIV-1 infected patients successfully treated with HAART
EVFThe NetherlandsCompletedVermeulen 2008 Abstract
Consortium Funder Duration Disease Area
SOLVE Horizon Europe 2024 – 2028  COVID-19
CoVICIS Horizon Europe 2021 – 2024 COVID-19
Corona Accelerated R&D in Europe (CARE) EU IMI 2020 – 2025 COVID-19
Acceleration of Novel Coronavirus Serological Test Development and Seroprevalence Study: An African-European Initiative (ASCENT) EDCTP 2020 – 2024 COVID-19
Indo-European Consortium for Next Generation Influenza Vaccine Innovation (INCENTIVE) EC Horizon 2020 Aug 2020 – Jul 2025 Influenza
Dissecting the Immunological Interplay between Poverty Related Diseases and Helminth Infections: An African-European Research Initiative (IDEA) EC FP7 Mar 2010 –
Sep 2015
Helminth Infections and its immunological interplay with HIV, TB and Malaria